N/A N=60 Randomized Single-blind Treatment

Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy

Endotracheal Intubation

Bottom Line

View on ClinicalTrials.gov: NCT01099969 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2018

Primary outcome: Primary: Intubation Time — 60.2; 48.8; 58.6; 40.7 seconds

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Glidescope videolaryngoscope (Device); McGrath videolaryngoscope (Device); Non-styletted Endotrol endotracheal tube (ETT) (Device); Regular endotracheal tube (ETT) with Gliderite stylet (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center, Houston
Primary completion: Jan 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Intubation Time	60.2; 48.8; 58.6; 40.7	—
PRIMARY Number of Intubation Attempts	13; 14; 14; 13; 1; 0	—
PRIMARY Number of Difficult Intubations	1; 0; 2; 0	—
SECONDARY Cormack and Lehane Grade of Laryngeal View	12; 11; 13; 13; 2; 4	—

Summary

The purpose of this study is to compare the safety and efficacy of Endotrol Tube compared to the conventional endotracheal tube in conjunction with the GlideRite stylet (Verathon Medical Inc, USA) during videolaryngoscopy assisted endotracheal intubation using a McGrath (Aircraft Medical Ltd., and distributed in the US by LMA North America, Inc.) video laryngoscope or a GlideScope (Verathon Medical Inc, USA). The investigators hypothesize that using the Endotrol tracheal tube, (Covidien, Colorado, USA) is safer and more efficacious than using the conventional endotracheal tube during McGrath video laryngoscope and/or GlideScope aided endotracheal intubation.

Eligibility Criteria

Inclusion Criteria

Age: 18-80 years old
ASA: I-III
Mallampati: I-III
Mouthopening: 2 FB or 80 years
ASA: IV
Mallampati: IV
Mouthopening < 2 FB 4cm
No risk for aspiration
No respiratory infection in past 10 days

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01099969). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.